What happened Specialty medical device maker Nevro (NYSE: NVRO) had an awful Thursday, with its shares collapsing by over 24% in late afternoon trading. Investors were punishing the company for a worse-than-expected second-quarter earnings report. So what In terms of headline numbers, Nevro's performance for the quarter was mixed. It earned $102.3 million in revenue, nearly double the $56.4 million it booked in the same period a year ago. However, the former didn't reach the collective analyst estimate of $104.5 million. Image source: Getty Images. The company, a healthcare device maker that specializes in pain-treatment solutions, did manage to narrow its net loss to $21.5 million ($0.62 per share) from Q2 2020's $41 million. That bettered the average prognosticator forecast of a $0.71-PER-SHARE deficit. In its earnings release, Nevro quoted its CEO D. Keith Grossman as saying, "The recovery of procedural volumes in the pain market generally and the [spinal cord stimulation] market specifically has been slower than we anticipated, impacting not only Q2 revenues, but in the case of lower trial procedures, revenue in future months as well." Now what As a result, Nevro trimmed its guidance for the third quarter. It now believes it will post $90 million to $93 million in revenue, which is down on both a quarter-over-quarter (by at least 14%) and year-over-year (minimally 7%) basis. Adjusted earnings before interest, taxes, depreciation, and amortization, or EBITDA, will be in the red, from $10 million to $12 million. A net profit/loss estimate was not provided. Due to the "lack of visibility around COVID-related recovery trends and timelines," the company has withdrawn its full-year outlook. 10 stocks we like better than NevroWhen our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Nevro wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.Source